Bartter and Gitelman syndromes are both inherited salt-wasting tubulopathies that produce hypokalemia, metabolic alkalosis, and elevated renin with normal blood pressure, but they differ in where the kidney tubule fails. Bartter syndrome strikes the thick ascending limb of the loop of Henle, causing profound salt loss, high urine calcium, and often growth failure in infancy. Gitelman syndrome strikes the distal convoluted tubule, causing milder salt loss, low urine calcium, and low magnesium that appears in adolescence or adulthood. The single most useful bedside separator is the urine calcium-to-creatinine ratio.
The Shared Mechanism: A Broken Sodium Chloride Reabsorber
Both conditions begin with the same logic. A transporter that normally pulls sodium chloride out of the tubular fluid fails, so salt escapes into the urine. The body responds by activating the renin-angiotensin-aldosterone system, which drives sodium reabsorption and potassium and hydrogen secretion in the collecting duct.
The result is a recognizable triad: low serum potassium, metabolic alkalosis, and high plasma renin activity with normal or low blood pressure. In plain terms: the kidney behaves as if the person is taking a diuretic every hour of every day.
The difference lies in the segment that fails. That segment determines the calcium handling, the magnesium handling, and the age of onset.
Bartter Syndrome: The Loop of Henle Defect
Bartter syndrome involves the thick ascending limb, where the sodium-potassium-2-chloride cotransporter (NKCC2) reabsorbs roughly 20 to 25 percent of filtered sodium. Five genetic subtypes are recognized, and onset ranges from severe antenatal disease to mild adult presentations.
Antenatal Bartter (types 1 and 2, affecting NKCC2 and ROMK) presents with severe polyhydramnios, premature birth at 28 to 34 weeks, and life-threatening dehydration in the first weeks. Classic Bartter (type 3, affecting CLCNKB) typically appears in the first two years of life with polyuria, vomiting, and failure to thrive. Type 4, linked to barttin, is associated with sensorineural deafness.
A key clue is urinary calcium. Because the loop of Henle normally reabsorbs about 25 percent of filtered calcium, its failure produces hypercalciuria, with urine calcium-to-creatinine ratios often above 0.2 mg/mg. That calcium loss drives nephrocalcinosis in a substantial share of antenatal cases, frequently visible on renal ultrasound by age 1.
Potassium in Bartter is low, often 2.0 to 2.5 mEq/L in severe infantile forms. Magnesium is usually normal or only mildly reduced.
Gitelman Syndrome: The Distal Convoluted Tubule Defect
Gitelman syndrome involves the thiazide-sensitive sodium chloride cotransporter (NCC) in the distal convoluted tubule, which reabsorbs only about 5 to 7 percent of filtered sodium. That smaller load explains the milder salt wasting.
Gitelman is far more common than Bartter, with an estimated prevalence of roughly 1 in 40,000, and it is the most frequently diagnosed inherited tubulopathy overall. Most cases trace to biallelic loss-of-function variants in SLC12A3. Onset is typically in adolescence or early adulthood, though many carriers remain undiagnosed for years.
Two features distinguish Gitelman from Bartter. First, because the distal tubule reabsorbs calcium, its failure reduces calcium excretion, so urine calcium-to-creatinine ratios are typically below 0.1 mg/mg and nephrocalcinosis is rare. Second, magnesium wasting is intrinsic, and serum magnesium falls below 1.5 mg/dL in most patients, sometimes below 1.0.
Potassium in Gitelman is usually 2.5 to 3.5 mEq/L, higher than in classic Bartter but still low enough to cause fatigue, cramps, and palpitations.
Quantified Comparison: Bartter vs Gitelman at a Glance
The table below reconciles the thresholds used throughout this article, including the 0.2 mg/mg urine calcium cutoff for Bartter and the 1.5 mg/dL serum magnesium cutoff for Gitelman.
| Feature | Bartter Syndrome | Gitelman Syndrome |
|---|---|---|
| Tubule segment | Thick ascending limb | Distal convoluted tubule |
| Typical gene | SLC12A1, KCNJ1, CLCNKB, BSND | SLC12A3 |
| Prevalence | About 1 in 1,000,000 | About 1 in 40,000 |
| Age of onset | Prenatal to age 2 years | Adolescence to adulthood |
| Serum potassium | 2.0 to 2.5 mEq/L (severe forms) | 2.5 to 3.5 mEq/L |
| Serum magnesium | Usually normal | Below 1.5 mg/dL in most |
| Urine calcium-to-creatinine ratio | Above 0.2 mg/mg | Below 0.1 mg/mg |
| Nephrocalcinosis | Common | Rare |
| Sensorineural deafness | In type 4 | Absent |
| Blood pressure | Normal or low | Normal or low |
Timeline of Disease Expression Across the Lifespan
The time course differs sharply, and the table below tracks when each feature typically appears. Rows reflect published natural-history patterns, not individual guarantees.
| Stage | Bartter Syndrome | Gitelman Syndrome |
|---|---|---|
| Prenatal | Polyhydramnios at 24 to 34 weeks | Usually unremarkable |
| Birth to 1 year | Prematurity, dehydration, growth failure | Almost never diagnosed |
| Age 1 to 5 years | Nephrocalcinosis on ultrasound, polyuria | Rarely diagnosed |
| Age 6 to 12 years | Growth delay, salt craving, cramps | Occasional incidental hypokalemia |
| Age 13 to 25 years | Stabilization, chronic potassium need | Fatigue, cramps, palpitations, tetany |
| Age 25 to 60 years | Risk of chronic kidney disease | Risk of chondrocalcinosis and arrhythmia |
| Beyond age 60 years | Progressive CKD in a minority | Joint disease, preserved kidney function |
Misconceptions and Non-Obvious Details
Several widely repeated claims need correction. The most important: Gitelman syndrome is not simply a mild form of Bartter, because the magnesium deficit creates its own complications.
First, patients with Gitelman are not rarely symptomatic. Surveys report muscle cramps in roughly 80 percent and fatigue in over 50 percent, which is why the condition is often mistaken for chronic fatigue or anxiety.
Second, Gitelman carries a real risk of cardiac arrhythmia. The combination of low potassium and low magnesium prolongs the QT interval, and torsades de pointes has been reported, so magnesium correction is not optional.
Third, Bartter does not spare the kidney long term. Chronic nephrocalcinosis and persistent hypokalemia are associated with reduced estimated glomerular filtration rate in a meaningful minority of adults, and the 2017 KDIGO guidance on chronic kidney disease staging applies for monitoring.
Fourth, the classic teaching that Bartter patients have no magnesium problem is incomplete. Patients treated with high-dose loop-acting potassium supplements can develop secondary magnesium wasting, so magnesium should be checked even in Bartter.
In plain terms: the calcium and magnesium numbers, not the potassium alone, tell you which syndrome you are facing.
Practical Steps: Diagnosis and What to Actually Do
Diagnosis rests on the paired urine and serum measurements. A urine calcium-to-creatinine ratio above 0.2 mg/mg points toward Bartter, and below 0.1 mg/mg toward Gitelman, in the setting of hypokalemic metabolic alkalosis with normal blood pressure. Genetic testing via a tubulopathy panel confirms the subtype when results will change management.
Positive actions for confirmed cases:
- Replace potassium with sustained-release chloride salts, targeting serum potassium above 3.0 mEq/L; doses of 40 to 120 mEq per day are common in Gitelman.
- Correct magnesium in Gitelman with oral magnesium chloride or magnesium oxide, often 300 to 500 mg of elemental magnesium per day, divided to limit diarrhea.
- Add potassium-sparing diuretics such as spironolactone 25 to 100 mg daily or amiloride 5 to 20 mg daily when supplements alone are insufficient, per the 2017 KDIGO guidance on CKD management.
- Monitor serum potassium, magnesium, and creatinine every 3 to 6 months, and obtain an ECG at diagnosis and after any dose change.
- Maintain high fluid and salt intake in Bartter, particularly in infants, to offset polyuria.
- Obtain a renal ultrasound at diagnosis in Bartter to screen for nephrocalcinosis.
Red-flag warnings that require urgent evaluation:
- Palpitations, syncope, or a corrected QT interval above 500 milliseconds.
- Serum potassium below 2.0 mEq/L or magnesium below 1.0 mg/dL.
- Vomiting, fever, or reduced oral intake in an infant with Bartter, which can precipitate shock within hours.
- New muscle weakness or paralysis suggesting severe hypokalemia.
- Seizures or tetany from severe hypomagnesemia.
Limits of Current Evidence
Several important gaps remain. Prevalence figures rest on genetic and clinical case series, and mild Gitelman cases are likely undercounted, so the true ratio may be broader than 25 to 1. No randomized controlled trial has compared potassium-replacement strategies in either syndrome, and dosing recommendations are extrapolated from expert consensus and small cohorts.
Long-term kidney outcomes in Bartter are described mainly in pediatric series, leaving adult trajectories uncertain. The role of novel agents, including NCC-sparing approaches under early investigation, remains hypothesis rather than established practice. Patients and clinicians should treat current guidelines as the best available framework, not a settled answer.